GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enlivex Therapeutics Ltd (FRA:1BT) » Definitions » Shiller PE Ratio

Enlivex Therapeutics (FRA:1BT) Shiller PE Ratio : (As of May. 24, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Enlivex Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Enlivex Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Enlivex Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enlivex Therapeutics Shiller PE Ratio Chart

Enlivex Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Enlivex Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Enlivex Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Enlivex Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enlivex Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enlivex Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Enlivex Therapeutics's Shiller PE Ratio falls into.



Enlivex Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Enlivex Therapeutics's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Enlivex Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.44/129.4194*129.4194
=-0.440

Current CPI (Dec. 2023) = 129.4194.

Enlivex Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -1.715 99.695 -2.226
201406 -2.283 100.560 -2.938
201409 -4.966 100.428 -6.400
201412 -7.137 99.070 -9.323
201503 -8.501 99.621 -11.044
201506 -9.266 100.684 -11.911
201509 -8.910 100.392 -11.486
201512 -12.485 99.792 -16.192
201603 -11.494 100.470 -14.806
201606 -7.832 101.688 -9.968
201609 -10.122 101.861 -12.860
201612 -7.205 101.863 -9.154
201703 -5.984 102.862 -7.529
201706 -3.560 103.349 -4.458
201709 -2.148 104.136 -2.670
201712 4.664 104.011 5.803
201803 -2.660 105.290 -3.270
201806 -2.328 106.317 -2.834
201809 -2.400 106.507 -2.916
201812 -3.313 105.998 -4.045
201903 -5.239 107.251 -6.322
201906 -0.991 108.070 -1.187
201909 -0.209 108.329 -0.250
201912 -0.252 108.420 -0.301
202003 -0.063 108.902 -0.075
202006 -0.204 108.767 -0.243
202009 -0.136 109.815 -0.160
202012 -0.353 109.897 -0.416
202103 -0.160 111.754 -0.185
202106 -0.141 114.631 -0.159
202109 -0.162 115.734 -0.181
202112 -0.239 117.630 -0.263
202203 -0.409 121.301 -0.436
202206 -0.511 125.017 -0.529
202209 -0.313 125.227 -0.323
202212 -0.368 125.222 -0.380
202303 -0.364 127.348 -0.370
202306 -0.342 128.729 -0.344
202309 -0.300 129.860 -0.299
202312 -0.440 129.419 -0.440

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Enlivex Therapeutics  (FRA:1BT) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Enlivex Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Enlivex Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Enlivex Therapeutics (FRA:1BT) Business Description

Traded in Other Exchanges
Address
14 Einstein Street, Nes Ziona, ISR, 7403618
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.

Enlivex Therapeutics (FRA:1BT) Headlines

No Headlines